ArticleNeuroradiology2026
Association between cerebrovascular imaging markers and glymphatic function in a large-scale cognitively normal population.
Article in Neuroradiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study aimed to investigate the association between cerebrovascular imaging markers and glymphatic function in cognitively normal individuals.
methodsThis retrospective study included 574 cognitively normal participants who underwent brain magnetic resonance imaging from January to October 2023. Glymphatic function was assessed using diffusion tensor image analysis along the perivascular space index (ALPS-index). Cerebrovascular imaging markers, including white matter hyperintensity (WMH) burden, cerebral microbleeds (CMBs), and choroid plexus volume (CPV), were quantified using automated segmentation methods. The presence of lacunes in the basal ganglia or old infarcts in other areas was visually determined. Associations between cerebrovascular markers and ALPS-index were analyzed using multivariable regression and partial correlation analyses.
resultsThe mean age of the included participants was 68.9 ± 10.4 years (male, 40.9%; hypertension, 43.7%; diabetes, 20.4%; Mini-Mental State Examination [MMSE] score, 27.6 ± 1.6). A lower ALPS-index, reflecting impaired glymphatic clearance, was significantly associated with higher WMH burden (β=-0.231, p < 0.001), increased CPV fraction (β=-0.234, p < 0.001), and a greater number of deep CMBs (β=-0.087, p = 0.038). The participants with basal ganglia lacunes (ALPS-index: 1.32 ± 0.19), old infarcts other than basal ganglia (ALPS-index: 1.34 ± 0.19), or both (ALPS-index: 1.27 ± 0.19) had significantly lower ALPS-indices than those without these conditions (ALPS-index: 1.43 ± 0.21; all, p < 0.001).
conclusionCerebrovascular imaging findings are significantly associated with glymphatic dysfunction in cognitively normal individuals, highlighting the need for further studies on glymphatic-targeted interventions in cerebrovascular disease prevention.
Indexed as
Identifiers
41003695What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.